⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 28, 2024Harm Reduction JournalOpen Access

Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs

Patrik Roser Mona Brunstein Michael Specka Jörg Timm Stefan Kühnhold Fabrizio Schifano Udo Bonnet Norbert Scherbaum

View Full Paper

Ask AI

Bookmark

Share

Abstract

Direct acting antivirals (DAAs) as a curative treatment of hepatitis C have been available for several years and have replaced interferon-containing therapies. However, treatment rates of people who inject drugs (PWID) are declining in Germany, putting the elimination of hepatitis C by 2030 at risk. This study aimed at elucidating the knowledge of, and attitude towards, hepatitis C treatment in a clinical sample of PWID.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roser et al. (2024) studied this question.

synapsesocial.com/papers/68e5a950b6db6435875433d9 https://doi.org/10.1186/s12954-024-01068-w

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era2024 · 12 citations
2<scp>HCV</scp>‐<scp>HIV</scp> co‐infection in people who inject drugs: Barriers to treatment and cure of <scp>HCV</scp> infection in the era of <scp>DAAs</scp>, a prospective study in Athens, Greece2024 · 2 citations
3Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting2024 · 6 citations
4Impact of Antiviral Therapy Scale‐Up Among People Who Inject Drugs in Scotland: Regional Evidence of Hepatitis C Virus EliminationOriginal Research · 2026 · 1 citations
5Cost effectiveness of hepatitis C direct acting agents2024 · 3 citations